Q-omics provides the consensus-scored HBA2 profile across patient tissues and cancer cell-line models. HBA2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HBA2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, HBA2 RNA expression shows 14,558 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where HBA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HBA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HBA2 survival associations across molecular data types. HBA2 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HBA2 RNA expression–survival associations across cancer types. High HBA2 expression shows unfavorable associations in ACC, COAD, ESCA and LUAD, but favorable associations in KIRC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HBA2 RNA expression.
This table summarizes HBA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for HBA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HBA2 shows lower tumor expression in THCA, COAD, LUSC, LUAD, LIHC and BRCA. The THCA box plot shows higher HBA2 RNA expression in normal versus tumor tissue (log2 FC = −2.954, t-test p < 0.001).
This table shows molecular features associated with HBA2 in patient tissues and cancer cell lines. In patient samples, HBA2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HBA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and PANCREAS.
